Objective: To analyze the rule of acupoint selection for cancer pain based on data mining.

Methods: The published literature regarding acupuncture for cancer pain in the recent 10 years was searched in PubMed, CNKI, VIP and Wanfang database. The acupoint selection was summarized and analyzed by TCMISS V2.5.

Results: Totally 68 literature was collected and 73 acupoint prescriptions were included, involving 117 acupoints. These acupoints were mainly in bladder meridian, stomach meridian, liver meridian and spleen meridian. Among them, 40 acupoints used more than 4 times were identified, and the top three acupoints were Zusanli (ST 36, 65 times), Neiguan (PC 6, 55 times) and Taichong (LR 3, 50 times). A total of 68 acupoint combinations used more than 19 times were identified, and the top three acupoint combinations were Zusanli (ST 36)-Neiguan (PC 6), Taichong (LR 3)-Zusanli (ST 36) and Zusanli (ST 36)-Sanyinjiao (SP 6). There were 103 acupoint combinations with strong association; based on the entropy clustering algorithm, 20 new acupoint combinations and 10 new acupoint prescriptions were obtained.

Conclusion: The main meridians for cancer pain are bladder meridian, stomach meridian, liver meridian and spleen meridian, with Zusanli (ST 36), Neiguan (PC 6), Taichong (LR 3), Hegu (LI 4), Sanyinjiao (SP 6) and points as core acupoints, and regulating spleen-stomach and treating -blood are the main principles.

Download full-text PDF

Source
http://dx.doi.org/10.13703/j.0255-2930.20190311-0001DOI Listing

Publication Analysis

Top Keywords

cancer pain
16
acupoint combinations
16
acupoint selection
12
selection cancer
8
pain based
8
acupoint
8
acupoint prescriptions
8
meridian
8
bladder meridian
8
meridian stomach
8

Similar Publications

Responsive cancer care in Asia: stigma and pain must be acknowledged and addressed.

Support Care Cancer

January 2025

Duke-NUS Medical School, Lien Centre for Palliative Care, 8 College Road, Level 4, Singapore, 169857, Singapore.

Purpose: This study investigates whether cancer-related stigma and pain among patients with advanced cancer influences their perceptions of receiving responsive care.

Methods: We surveyed 2138 advanced cancer patients from 11 hospitals in eight Asian countries. Participants rated their most recent healthcare visit and a hypothetical patient's experience described in vignettes concerning dignity, clarity of information, and involvement in decision-making.

View Article and Find Full Text PDF

Single-fraction stereotactic body radiation therapy (SF-SBRT) for peripheral lung tumors was reviewed. Medically inoperable peripheral lung tumors eligible for SF-SBRT 34 Gray were treated. Patient characteristics, treatment and toxicity parameters were retrospectively collected, and toxicities were evaluated.

View Article and Find Full Text PDF

Globally, an estimated 300 million individuals have sickle cell trait (SCT), the carrier state for sickle cell disease. While sickle cell disease (SCD) is associated with increased morbidity and shortened lifespan, SCT has a lifespan comparable to that of the general population. However, "sickle cell crisis" has been used as a cause of death for decedents with SCT in reports of exertion-related death in athletes, military personnel, and individuals in police custody.

View Article and Find Full Text PDF

Objectives: Endoscopic full-thickness resection for gastric submucosal tumors is gradually gaining popularity, and secure and amenable closure is key to its success. This study aimed to compare the reopenable clip over-the-line method with the purse-string method for defect closure after endoscopic full-thickness resection for gastric submucosal tumors.

Methods: This historical control trial included 37 consecutive patients with 37 gastric submucosal tumors, who underwent endoscopic full-thickness resection between January 2021 and July 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!